Thrombin-Treated Endothelium Primes Neutrophil Functions: Inhibition by Platelet-Activating Factor Receptor Antagonists
- 1 June 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 45 (6) , 483-490
- https://doi.org/10.1002/jlb.45.6.483
Abstract
We have shown previously that fluid phase platelet-activating factor (PAF) can enhance or “prime” polymorphonuclear (PMN) responses to subsequent stimulation with agonists such as formyl-methionine-leucine-phenylalanine (FMLP). Since thrombin induces PAF production in endothelial cells, we tested whether this thrombin-provoked endothelial PAF primes responses of marginateci PMNs. Monolayers of human umbilical vein endothelial cells were exposed to either thrombin (0.5-5.0 units/ml) or buffer for up to 5 min and then PMNs were layered on top of the endothelial cells. After a further 5 min incubation, the PMNs were stimulated with a suboptimal concentration of FMLP (10-7 M), and their superoxide production, elastase release, adhesion to endothelium, and capacity to cause endothelial cell lysis and detachment were assessed. Thrombin pretreatment significantly enhanced each of these FMLP-stimulated neutrophil responses. The extent of this enhancement correlated with both the dose and duration of thrombin treatment of endothelial cells and also the duration of PMN incubation with thrombin-exposed endothelium. Evidence that the augmentation was due to endothelial-derived PAF was obtained as follows: (1) thrombin induced [3H]acetate incorporation into endothelial PAF (assayed in lipid extracts); (2) antithrombin III conjointly inhibited this [3H]acetate uptake and prevented the priming effect of thrombin-treated endothelium on PMN responses; and (3) the PAF receptor antagonist BN52021. when preincubated with PMNs, also effectively blocked the enhancement of PMN responses. We conclude that thrombin stimulation of endothelial cells initiates a sequence of events culminating in the production of PAF—a membrane phospholipid capable of priming marginated PMNs. We suggest that this coagulation-fostered endothelial PMN interaction may underlie a paracrine response that may potentiate PMN-mediated endothelial injury during sepsis and other thrombin-generating disorders.Keywords
This publication has 26 references indexed in Scilit:
- The release of platelet-activating factor from human endothelial cells in culture.The Journal of Immunology, 1983
- Release of platelet activating factor in rabbits with antibody-mediated injury of the lung: the role of leukocytes and of pulmonary endothelial cells.The Journal of Immunology, 1983
- Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment.Journal of Clinical Investigation, 1981
- COMPLEMENT-INDUCED GRANULOCYTE AGGREGATION INVIVO1981
- 1-O-ALKYL-SN-GLYCERYL-3-PHOSPHORYLCHOLINES - A NOVEL CLASS OF NEUTROPHIL STIMULANTS1981
- Physicochemical and Functional Identity of Rabbit Platelet-Activating Factor (PAF) Released in Vivo during IgE Anaphylaxis with PAF Released in Vitro from IgE Sensitized BasophilsThe Journal of Immunology, 1979
- Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site.Journal of Biological Chemistry, 1979
- Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.Journal of Clinical Investigation, 1978
- The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes.Journal of Clinical Investigation, 1975
- THE EFFECT OF DIISOPROPYL FLUOROPHOSPHATE ON THE PROTEINASE AND ESTERASE ACTIVITIES OF THROMBIN AND ON PROTHROMBIN AND ITS ACTIVATORSJournal of Biological Chemistry, 1956